NASDAQ:TLRY 8 October 2025 - 9 January 2026

Tilray shares jumped nearly 9% to $9.95 in premarket trading after reporting fiscal Q2 revenue of $217.5 million and a narrowed net loss of $43.5 million. The company reaffirmed its full-year adjusted profit target and said it moved to a net cash position. Gross margin slipped, and craft beer sales remained under pressure. Traders are watching if the gains hold at the open.

Tilray Brands shares traded near $10.53 on December 24, 2025, following sharp gains in the second half of the year. President Donald Trump signed an executive order on December 18 to begin the process of reclassifying marijuana from Schedule I to Schedule III. The move sparked volatility across cannabis stocks, with prices swinging as investors weighed the potential impact. The order does not legalize cannabis but directs federal agencies to review its status.

Tilray Brands (TLRY) soared 44% to $12.15 on Dec. 12, with trading volume reaching 81.58 million shares after reports that Donald Trump may push to loosen federal marijuana restrictions. Shares gained nearly 69% for the week. After hours, TLRY traded as high as $13.14. The White House said no final decision has been made on marijuana rescheduling.

Tilray Brands posted record Q1 2026 revenue of $209.5 million and a surprise net profit of $1.5 million, sending shares up over 10% pre-market. The stock has quadrupled since July 2025, lifted by optimism over potential U.S. cannabis reform and recent political endorsements. Wall Street remains cautious, with a consensus “Hold” rating and a $1.90 price target. Volatility remains high as investors watch for policy changes and earnings updates.

Tilray Brands shares have soared about 300% since July 2025, trading near $1.70–$1.80 after bipartisan U.S. support for marijuana decriminalization and Donald Trump’s endorsement of CBD. The company reports earnings Oct. 9, with analysts expecting a net loss of $0.03 per share on $206 million revenue. Tilray’s beverage sales rose 19% last year, while international medical cannabis revenue jumped 71% in the latest quarter.

Tilray Brands shares surged nearly 300% since July 2025, peaking at $1.88 on September 29 after a White House video endorsed CBD and GOP senators backed cannabis rescheduling. The rally was fueled by a short squeeze, with trading volume jumping to 371 million shares. Despite the spike, Tilray reported a $1.26 billion loss in fiscal 2025 and shrinking core cannabis sales. The company holds $256 million in cash and has reduced debt.